Viva Vision Biotech Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 63

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 26

Viva Vision Biotech General Information

Description

Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior and posterior segment eye diseases. The company provides clinical-stage drug candidates and a robust R&D pipeline, enabling patients and healthcare systems with novel treatment options, improved efficacy, and solutions for unmet ocular medical needs.

Contact Information

Formerly Known As
Vivo Biotech (Shanghai) Co., Ltd.
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 4020, Building B, North Zone, Gene Valley
  • Ouhai District
  • Wenzhou, Zhejiang 900000
  • China
+86 0577
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • Room 4020, Building B, North Zone, Gene Valley
  • Ouhai District
  • Wenzhou, Zhejiang 900000
  • China
+86 0577

Viva Vision Biotech Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Viva Vision Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. IPO 13-Feb-2026 Announced Generating Revenue
13. Secondary Transaction - Private 01-Jan-2026 Completed Generating Revenue
12. Later Stage VC (Series D2) 27-Nov-2025 Completed Generating Revenue
11. Secondary Transaction - Private 01-May-2025 Completed Generating Revenue
10. Later Stage VC (Series D2) 31-Dec-2024 Completed Generating Revenue
9. Secondary Transaction - Private 01-Apr-2023 Completed Clinical Trials - Phase 2
8. Secondary Transaction - Private 01-Nov-2022 Completed Clinical Trials - Phase 2
7. Secondary Transaction - Private 01-Feb-2022 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series D) 09-Aug-2021 $46.3M $65.6M Completed Clinical Trials - Phase 2
5. Secondary Transaction - Private 01-Jan-2021 $19.3M Completed Clinical Trials - Phase 2
To view Viva Vision Biotech’s complete valuation and funding history, request access »

Viva Vision Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior an
Drug Discovery
Wenzhou, China
63 As of 2026

Heidelberg, Germany
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Viva Vision Biotech Competitors (26)

One of Viva Vision Biotech’s 26 competitors is Novaliq, a Venture Capital-Backed company based in Heidelberg, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novaliq Venture Capital-Backed Heidelberg, Germany
EyePoint Corporation Watertown, MA
EyeD Pharma Venture Capital-Backed Seraing, Belgium
Astellas Pharma Corporation Tokyo, Japan
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 5 of 26 competitors. Get the full list »

Viva Vision Biotech Patents

Viva Vision Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026201113-A1 Intranasal compositions comprising a jak inhibitor for inflammatory upper respiratory disease Pending 28-Mar-2025
WO-2026170436-A1 Derivative of jak inhibitor Pending 14-Feb-2025
WO-2026119018-A1 Ngf-containing ophthalmic composition and use thereof Pending 02-Dec-2024
WO-2026082117-A1 Jak inhibitors for treating inflammatory eye conditions Pending 17-Oct-2024
WO-2025160705-A1 Preparation method for lfa-1 inhibitor Pending 29-Jan-2024
To view Viva Vision Biotech’s complete patent history, request access »

Viva Vision Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viva Vision Biotech Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
Wanlian Tianze Capital Investment Venture Capital Minority
Guangdong Technology Financial Group Government Minority
Guangzhou Industrial Investment Holding Group Government Minority
Hunan Energy Group Corporation Minority
The Innovation and Technology Commission Government Minority
You’re viewing 5 of 26 investors. Get the full list »

Viva Vision Biotech Investments (3)

Viva Vision Biotech’s most recent deal was a Joint Venture with Joint Venture (VivaVision / Jiangxi Shanliang Pharmaceutical). The deal was made on 06-Jun-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (VivaVision / Jiangxi Shanliang Pharmaceutical) 06-Jun-2024 Joint Venture Other Consumer Durables
Therapies for Retinal Diseases (Everads / VivaVision Biopharma) 06-Jan-2023 Joint Venture Drug Discovery
E-nitiateBio 23-Nov-2020 Joint Venture Drug Discovery
To view Viva Vision Biotech’s complete investments history, request access »

Viva Vision Biotech FAQs

  • When was Viva Vision Biotech founded?

    Viva Vision Biotech was founded in 2016.

  • Where is Viva Vision Biotech headquartered?

    Viva Vision Biotech is headquartered in Wenzhou, China.

  • What is the size of Viva Vision Biotech?

    Viva Vision Biotech has 63 total employees.

  • What industry is Viva Vision Biotech in?

    Viva Vision Biotech’s primary industry is Drug Discovery.

  • Is Viva Vision Biotech a private or public company?

    Viva Vision Biotech is a Private company.

  • What is Viva Vision Biotech’s current revenue?

    The current revenue for Viva Vision Biotech is .

  • How much funding has Viva Vision Biotech raised over time?

    Viva Vision Biotech has raised $107M.

  • Who are Viva Vision Biotech’s investors?

    Wanlian Tianze Capital Investment, Guangdong Technology Financial Group, Guangzhou Industrial Investment Holding Group, Hunan Energy Group, and The Innovation and Technology Commission are 5 of 26 investors who have invested in Viva Vision Biotech.

  • Who are Viva Vision Biotech’s competitors?

    Novaliq, EyePoint, EyeD Pharma, Astellas Pharma, and Crinetics Pharmaceuticals are some of the 26 competitors of Viva Vision Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process